Get started
Author

Alisa Damnernsawad

Observed names: A Damnernsawad, A. Damnernsawad, Damnernsawad, Alisa
ORCID: 0000-0001-7565-076X
Observed ORCID: 0000-0001-7565-076X
OpenAlex ID: A5040407244
The IRP1-HIF-2α Axis Coordinates Iron and Oxygen Sensing with Erythropoiesis and Iron Absorption
2013 · Sheila A. Anderson, Christopher P. Nizzi, et al. · Cell Metabolism · 214
Genome-wide identification of genes involved in tolerance to various environmental stresses inSaccharomyces cerevisiae
2009 · C. Auesukaree, A. Damnernsawad, et al. · Journal of Applied Genetics · 176
CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
2018 · David K. Edwards, Kevin Watanabe-Smith, et al. · Blood · 106
NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions
2013 · Jinyong Wang, Guangyao Kong, et al. · Blood · 61
Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm
2014 · Guangyao Kong, Mark Wunderlich, et al. · Journal of Clinical Investigation · 51
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
2019 · Su Lin Lim, Alisa Damnernsawad, et al. · Haematologica · 45
PDF
Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis
2016 · G Kong, Y-I Chang, et al. · Leukemia · 43
Kras is Required for Adult Hematopoiesis
2016 · Alisa Damnernsawad, Guangyao Kong, et al. · Stem Cells · 41
PDF
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia
2020 · Alisa Damnernsawad, Daniel Bottomly, et al. · Haematologica · 39
PDF
Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment
2018 · Haijiao Zhang, Beth Wilmot, et al. · Blood · 33
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
2022 · Sara J. C. Gosline, Cristina Tognon, et al. · Clinical Proteomics · 26
PDF
A novel activating JAK1 mutation in chronic eosinophilic leukemia
2021 · William Shomali, Alisa Damnernsawad, et al. · Blood Advances · 22
PDF
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
2024 · Rucha V. Modak, Katia G. de Oliveira Rebola, et al. · Clinical Cancer Research · 17
Nras Q61R/+ and Kras −/− cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
2021 · Zhi Wen, Grant Yun, et al. · Blood · 14
Evaluation of allelic strength of human TET 2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation
2014 · Yuan‐I Chang, Alisa Damnernsawad, et al. · British Journal of Haematology · 14
Embryonic Expression of NrasG 12 D Leads to Embryonic Lethality and Cardiac Defects
2021 · Xiaona You, Myung-Jeom Ryu, et al. · Frontiers in Cell and Developmental Biology · 9
PDF
Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity
2020 · Lan Luo, Yuhong Chen, et al. · The Journal of Immunology · 8
The mystery of oncogenicKRAS: Lessons from studying its wild-type counter part
2016 · Yuan-I Chang, Alisa Damnernsawad, et al. · Small GTPases · 5
PDF
Abstract 1429: Characterization of trametinib combined with venetoclax in acute myeloid leukemia (AML) treatment
2021 · Alisa Damnernsawad, Christopher A. Eide, et al. · Cancer Research · 4
Data from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
2024 · Rucha V. Modak, Katia G. de Oliveira Rebola, et al. · 1
Abstract 5942: An integrated approach reveals novel extrinsic pathways and cytokine signatures associated with drug response in acute myeloid leukemia
2020 · Rucha V. Modak, Alisa Damnernsawad, et al. · Cancer Research · 1
Abstract 4763: Genome-wide CRISPR screening identifies TSC1 as a regulator of sorafenib resistance in acute myeloid leukemia
2019 · Alisa Damnernsawad, Tamilla Nechiporuk, et al. · Cancer Research · 1
Kras Plays An Important Role In Generating Differentiated Blood Cells
2013 · Alisa Damnernsawad, Guangyao Kong, et al. · Blood · 1
Supp Table S3 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
2024 · Rucha V. Modak, Katia G. de Oliveira Rebola, et al.
Star Table 1 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
2024 · Rucha V. Modak, Katia G. de Oliveira Rebola, et al.
PDF
Works count: 61
Citation count: 932
H-index: 14
I10-index: 15
Year
Topic
Type